Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12747393 | 0.91 | TK1 (0.48) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL769371 | 0.91 | TK1 (0.48) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL1468928 | 0.91 | TK1 (0.48) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL13017964 | 0.90 | TK1 (0.49) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL2692709 | 0.81 | SLC28A1 (0.45) | — | |
| SCHEMBL14827484 | 0.81 | TK1 (0.48) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL769335 | 0.81 | TK1 (0.45) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL14827485 | 0.81 | TK1 (0.45) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL26269232 | 0.81 | TK2 (0.50) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL25504803 | 0.81 | TK2 (0.50) | ALDH1A1LMNAALBPOLBADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088904-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | HNRNPM, POLM, RNMT | TK1 252/4885ALDH1A1 3650/4885LMNA 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.